Verici Dx Plc (VRCI) - Net Assets
Based on the latest financial reports, Verici Dx Plc (VRCI) has net assets worth GBX2.48 Million GBX (≈ $301.99 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX4.54 Million ≈ $553.00 USD) and total liabilities (GBX2.06 Million ≈ $251.01 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Verici Dx Plc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX2.48 Million |
| % of Total Assets | 54.61% |
| Annual Growth Rate | -28.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.54 |
Verici Dx Plc - Net Assets Trend (2020–2024)
This chart illustrates how Verici Dx Plc's net assets have evolved over time, based on quarterly financial data. See Verici Dx Plc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Verici Dx Plc (2020–2024)
The table below shows the annual net assets of Verici Dx Plc from 2020 to 2024. For live valuation and market cap data, see Verici Dx Plc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX5.26 Million ≈ $640.60 |
+47.98% |
| 2023-12-31 | GBX3.56 Million ≈ $432.91 |
-69.09% |
| 2022-12-31 | GBX11.51 Million ≈ $1.40K |
-3.97% |
| 2021-12-31 | GBX11.98 Million ≈ $1.46K |
-38.93% |
| 2020-12-31 | GBX19.62 Million ≈ $2.39K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Verici Dx Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3434499300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX310.00K | 5.89% |
| Other Comprehensive Income | GBX3.67 Million | 69.65% |
| Other Components | GBX40.37 Million | 766.72% |
| Total Equity | GBX5.26 Million | 100.00% |
Verici Dx Plc Competitors by Market Cap
The table below lists competitors of Verici Dx Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sutton Harbour Holdings plc
LSE:SUH
|
$69.57K |
|
Walker Crips Group PLC
LSE:WCW
|
$69.94K |
|
TROUBADOUR RESOURCES INC.
F:2QD0
|
$70.07K |
|
Argo Blockchain PLC
LSE:ARB
|
$70.15K |
|
Proteome Sciences PLC
LSE:PRM
|
$68.28K |
|
Seed Innovations Ltd
LSE:SEED
|
$67.47K |
|
CPPGroup Plc
LSE:CPP
|
$67.31K |
|
Mothercare PLC
LSE:MTC
|
$67.21K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Verici Dx Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,558,000 to 5,265,000, a change of 1,707,000 (48.0%).
- Net loss of 5,874,000 reduced equity.
- New share issuances of 8,196,000 increased equity.
- Other comprehensive income increased equity by 67,999.
- Other factors decreased equity by 682,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-5.87 Million | -111.57% |
| Share Issuances | GBX8.20 Million | +155.67% |
| Other Comprehensive Income | GBX68.00K | +1.29% |
| Other Changes | GBX-683.00K | -12.97% |
| Total Change | GBX- | 47.98% |
Book Value vs Market Value Analysis
This analysis compares Verici Dx Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.66x to 16.57x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | GBX0.23 | GBX0.38 | x |
| 2021-12-31 | GBX0.08 | GBX0.38 | x |
| 2022-12-31 | GBX0.07 | GBX0.38 | x |
| 2023-12-31 | GBX0.02 | GBX0.38 | x |
| 2024-12-31 | GBX0.02 | GBX0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Verici Dx Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -111.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -175.92%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.42x
- Recent ROE (-111.57%) is above the historical average (-112.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -36.19% | 0.00% | 0.00x | 1.03x | GBX-9.06 Million |
| 2021 | -69.50% | 0.00% | 0.00x | 1.15x | GBX-9.53 Million |
| 2022 | -98.70% | 0.00% | 0.00x | 1.24x | GBX-12.51 Million |
| 2023 | -245.47% | -862.19% | 0.14x | 2.09x | GBX-9.09 Million |
| 2024 | -111.57% | -175.92% | 0.45x | 1.42x | GBX-6.40 Million |
Industry Comparison
This section compares Verici Dx Plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $444,830,674
- Average return on equity (ROE) among peers: -46.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Verici Dx Plc (VRCI) | GBX2.48 Million | -36.19% | 0.83x | $69.05K |
| Abingdon Health Plc (ABDX) | $2.75 Million | -122.74% | 2.99x | $351.31K |
| ANGLE plc (AGL) | $546.00K | -64.47% | 0.92x | $94.18K |
| genedrive plc (GDR) | $5.36 Million | -132.02% | 0.27x | $162.85K |
| Integrated Diagnostics Holdings PLC (IDHC) | $3.10 Billion | 16.46% | 0.86x | $320.89 Million |
| LungLife AI Inc (LLAI) | $-3.10 Million | 0.00% | 0.00x | $15.48K |
| Oxford Biodynamics PLC (OBD) | $7.74 Million | -22.34% | 0.16x | $86.14K |
| Proteome Sciences PLC (PRM) | $-270.00K | 0.00% | 0.00x | $68.28K |
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more